Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of
Glivec® in combination with mFOLFOX-Avastin®. Patients will be enrolled into each dose level
in 3 patient cohorts. Additional cohorts will be enrolled, or dose levels opened, subject to
the toxicities observed. Once the MTD has been determined the dose level below will be
re-opened and extra patients, to a total of 15, will be enrolled.